In summary, our data add to the emerging concept that peripheral innate immune dysfunction may contribute to PD, however further work is required to determine the mechanisms by which this occurs, and to understand the implications for LRRK2 kinase inhibitor therapies to treat PD. This evidence concerns the gene LRRK2 and Parkinson disease.